United Therapeutics (UTHR) Tops Q2 EPS by 67c
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $501.27 -2.04%
Financial Fact:
Net product sales: 408.2M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Net product sales: 408.2M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $5.24, $0.67 better than the analyst estimate of $4.57. Revenue for the quarter came in at $596.5 million versus the consensus estimate of $524.18 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
- LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
- Lument Finance Trust (LFT) Misses Q2 EPS by 17c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
